Servier and Black Diamond Therapeutics have signed a licensing agreement for a targeted therapy, BDTX-4933, to treat solid tumours. Servier will be responsible for the development and the global ...

Alongside BDTX-4933, the company is also progressing a brain-penetrant BDTX-1535 in a Phase II trial for NSCLC. "Servier and Black Diamond sign deal for solid tumours therapy" was originally ...